Drugs / MILVETEROL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00358488 | Apr 2006 → Jan 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00354666 | Sep → Dec 2004 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MILVETEROL | ChEMBL registry synonym — accepted as the source's own label CHEMBL1940832 ↗ |
| Known as | GSK-159797C | ChEMBL registry synonym — accepted as the source's own label CHEMBL1940832 ↗ |
| Known as | GSK159797 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00354666 ↗ |
| Known as | Milveterol hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1940832 ↗ |
| Known as | MILVETEROL HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1940832 ↗ |
| Known as | TD3327 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1940832 ↗ |
| Action | Activate | “Beta-2 adrenergic receptor agonist” CHEMBL1940832 ↗1“long-acting beta-agonist” NCT00358488 ↗ |
| Modality | Small molecule | — CHEMBL1940832 ↗ |
| Route | Inhaled | “Inhaled GSK159797 Delivered by Dry Powder Inhaler” NCT00354666 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor agonist” CHEMBL1940832 ↗ |